Andrew Witty - UnitedHealth Group CEO
| UNH Stock | MXN 12,094 446.15 3.83% |
CEO
Mr. Andrew Philip Witty is re designated as Chief Executive Officer of Optum, Executive Vice President, Director of the Company, effective July 1, 2018. Sir Andrew Witty was CEO and a board member of GlaxoSmithKline plc, a global pharmaceutical company, from 2008 to April, 2017. He joined GSK in 1985 and, prior to 2008, served in various senior roles in Europe, South Africa, the U.S. and Asia. Witty is Chancellor of the University of Nottingham, a British public research university, and has served in that capacity since January 2013. He is a Business Ambassador for the U.K. Prime Minister. Witty serves on the Singapore Economic Development Board International Advisory Committee, the Council at the London School of Hygiene and Tropical Medicine, and as an Advisor to the Bill and Melinda Gates Foundation. Witty was knighted in the 2012 New Year Honours for services to the economy and the U.K. pharmaceutical industry. He also serves on the board of G1 Therapeutics, Inc. since 2021.
| Age | 54 |
| Tenure | 3 years |
| Professional Marks | MBA |
| Phone | 952 936 1300 |
| Web | https://www.unitedhealthgroup.com |
Andrew Witty Latest Insider Activity
Tracking and analyzing the buying and selling activities of Andrew Witty against UnitedHealth Group stock is an integral part of due diligence when investing in UnitedHealth Group. Andrew Witty insider activity provides valuable insight into whether UnitedHealth Group is net buyers or sellers over its current business cycle. Note, UnitedHealth Group insiders must abide by specific rules, including filing SEC forms every time they buy or sell UnitedHealth Group'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Andrew Witty over a year ago Payment of 372 shares by Andrew Witty of UnitedHealth Group subject to Rule 16b-3 | ||
Andrew Witty over a year ago Acquisition by Andrew Witty of 100 shares of UnitedHealth Group subject to Rule 16b-3 |
UnitedHealth Group Management Efficiency
The company has return on total asset (ROA) of 0.0776 % which means that it generated a profit of $0.0776 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2535 %, meaning that it generated $0.2535 on every $100 dollars invested by stockholders. UnitedHealth Group's management efficiency ratios could be used to measure how well UnitedHealth Group manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 4 records | CEO Age | ||
| Fabian Zanetto | Grupo Sports World | 49 | |
| David Burritt | United States Steel | 68 | |
| Brian Humphries | Cognizant Technology Solutions | 49 | |
| BCom AMP | The Bank of | 65 | |
Management Performance
| Return On Equity | 0.25 | |||
| Return On Asset | 0.0776 |
UnitedHealth Group Leadership Team
Elected by the shareholders, the UnitedHealth Group's board of directors comprises two types of representatives: UnitedHealth Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UnitedHealth. The board's role is to monitor UnitedHealth Group's management team and ensure that shareholders' interests are well served. UnitedHealth Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UnitedHealth Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gail Wilensky, Independent Director | ||
| Richard Burke, Independent Chairman of the Board | ||
| Valerie Rice, Independent Director | ||
| Andrew Witty, Group President, Chief Executive Officer, Executive Vice President, Director | ||
| Sir Witty, CEO Director | ||
| Stephen Hemsley, Non-Executive Chairman of the Board | ||
| John Rex, Chief Financial Officer, Executive Vice President | ||
| Dirk McMahon, Chief Executive Officer - UnitedHealthcare | ||
| Zachary Sopcak, VP Relations | ||
| John Noseworthy, Independent Director | ||
| Jennifer Smoter, VP Officer | ||
| William Ballard, Independent Director | ||
| Glenn Renwick, Independent Director | ||
| Rupert Bondy, Ex Officer | ||
| Sandeep Dadlani, Ex Officer | ||
| Michele Hooper, Independent Director | ||
| Timothy Flynn, Independent Director | ||
| Thomas Roos, Senior Vice President, Chief Accounting Officer | ||
| Matthew Friedrich, Executive Vice President Chief Legal Officer | ||
| D Wilson, Executive Vice President - Human Capital | ||
| F McNabb, Independent Director | ||
| Marianne Short, Executive Vice President Chief Legal Officer | ||
| David Wichmann, CFO, Executive Vice President and Presidentident - UnitedHealth Group Operations | ||
| Brian Thompson, Ex UnitedHealthcare | ||
| James Barry, Director Pennsylvania |
UnitedHealth Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is UnitedHealth Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.25 | |||
| Return On Asset | 0.0776 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 9.95 T | |||
| Shares Outstanding | 934.35 M | |||
| Shares Owned By Insiders | 0.46 % | |||
| Shares Owned By Institutions | 89.00 % | |||
| Price To Earning | 25.88 X | |||
| Price To Book | 6.64 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for UnitedHealth Stock Analysis
When running UnitedHealth Group's price analysis, check to measure UnitedHealth Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UnitedHealth Group is operating at the current time. Most of UnitedHealth Group's value examination focuses on studying past and present price action to predict the probability of UnitedHealth Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UnitedHealth Group's price. Additionally, you may evaluate how the addition of UnitedHealth Group to your portfolios can decrease your overall portfolio volatility.